{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-022852","form_type":"8-K","ticker":"TVGN","cik":"0001860871","company_name":"Tevogen Bio Holdings Inc.","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.334639+00:00","generated_at":"2026-06-13T15:06:33.198126+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Semper Paratus Acquisition Corp. enters definitive merger with Tevogen Bio at $1.2B enterprise value","bullets":["Merger consideration: $1.2B in Semper Paratus Class A common stock; plus up to 20M earnout shares at price targets of $15, $17.50, $20.","Post-closing board: 7 directors, 6 designated by Tevogen Bio; CEO and CFO of Tevogen to continue in same roles.","Closing conditions: minimum $25M cash at close, shareholder approvals, SEC registration, and $5M net tangible assets.","Outside date: December 5, 2023; no termination fees; equity line of credit $35M-$60M possible but not required."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-022852","json":"https://secwatch.observer/filing/0001493152-23-022852.json","markdown":"https://secwatch.observer/filing/0001493152-23-022852.md","text":"https://secwatch.observer/filing/0001493152-23-022852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/0001493152-23-022852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:06:33.198126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab5d0e27373bdc21b03201e4927cca05fe147cda","claim":"Tevogen Bio Holdings Inc. entered into Merger Agreement with Semper Paratus Acquisition Corporation, Semper Merger Sub, Inc., SSVK Associates, LLC (effective 2023-06-28).","evidence_excerpt":"On June 28, 2023, Semper Paratus Acquisition Corporation, a Cayman Island exempted company (“ Semper Paratus ”) entered into an Agreement and Plan of Merger by and among Semper Paratus, Semper Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Semper Paratus (“ Merger Sub ”), SSVK Associates, LLC, Semper Paratus’ sponsor (the “ Sponsor ”), in its capacity as purchaser representative, Tevogen Bio Inc, a Delaware corporation (“ Tevogen Bio ”), and Ryan Saadi, in his capacity as seller representative (as may be amended and/or restated from time to time, the “ Merger Agreement ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/0001493152-23-022852-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Semper Paratus Acquisition Corporation, Semper Merger Sub, Inc., SSVK Associates, LLC"},{"label":"Effective","value":"2023-06-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}